80 related articles for article (PubMed ID: 28259943)
1. Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone.
Prashanth N ; Meghana P ; Sandeep Kumar Jain R ; Pooja S Rajaput ; Satyanarayan N D ; Raja Naika H ; Kumaraswamy H M
Sci Total Environ; 2024 Mar; 914():169727. PubMed ID: 38163613
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
Wei R; Penso NEC; Hackman RM; Wang Y; Mackenzie GG
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31405071
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M; Domoto T; Takenaka S; Bolidong D; Takeuchi O; Miyashita T; Minamoto T
Cancer Sci; 2020 Dec; 111(12):4405-4416. PubMed ID: 32986894
[TBL] [Abstract][Full Text] [Related]
4. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
[TBL] [Abstract][Full Text] [Related]
5. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA
Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca‑2 and PANC‑1 cells.
He J; Bugde P; Li J; Biswas R; Li S; Yang X; Tian F; Wu Z; Li Y
Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37975256
[TBL] [Abstract][Full Text] [Related]
7. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
Lee SH; Hwang HK; Lee WJ; Kang CM
Cell Oncol (Dordr); 2021 Dec; 44(6):1363-1371. PubMed ID: 34791637
[TBL] [Abstract][Full Text] [Related]
8. RETRACTED: Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Surgery; 2004 Aug; 136(2):261-9. PubMed ID: 15300189
[TBL] [Abstract][Full Text] [Related]
9. Overcoming drug resistance in pancreatic cancer.
Long J; Zhang Y; Yu X; Yang J; LeBrun DG; Chen C; Yao Q; Li M
Expert Opin Ther Targets; 2011 Jul; 15(7):817-28. PubMed ID: 21391891
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative Activity of Piceamycin by Regulating
Lee JH; Choi JH; Lee KM; Lee MW; Ku JL; Oh DC; Shin YH; Kim DH; Cho IR; Paik WH; Ryu JK; Kim YT; Lee SH; Lee SK
Biomol Ther (Seoul); 2024 Jan; 32(1):123-135. PubMed ID: 38148558
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer: translational research aspects and clinical implications.
Ansari D; Chen BC; Dong L; Zhou MT; Andersson R
World J Gastroenterol; 2012 Apr; 18(13):1417-24. PubMed ID: 22509073
[TBL] [Abstract][Full Text] [Related]
12. Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Urey C; Andersson B; Ansari D; Sasor A; Said-Hilmersson K; Nilsson J; Andersson R
Scand J Gastroenterol; 2017 May; 52(5):595-600. PubMed ID: 28270046
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Biological Evaluation of Sclareolide-Indole Conjugates and Their Derivatives.
Cheng Y; Lyu X; Liu C; Wang X; Cheng J; Zhang D; Meng X; Zhao Y
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838727
[TBL] [Abstract][Full Text] [Related]
14. Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer.
Laurella LC; Mirakian NT; Garcia MN; Grasso DH; Sülsen VP; Papademetrio DL
Molecules; 2022 May; 27(11):. PubMed ID: 35684434
[TBL] [Abstract][Full Text] [Related]
15. "Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer.
Randazzo O; Papini F; Mantini G; Gregori A; Parrino B; Liu DSK; Cascioferro S; Carbone D; Peters GJ; Frampton AE; Garajova I; Giovannetti E
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142664
[TBL] [Abstract][Full Text] [Related]
16. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
Luo W; Yang G; Qiu J; Luan J; Zhang Y; You L; Feng M; Zhao F; Liu Y; Cao Z; Zheng L; Zhang T; Zhao Y
Cancer Med; 2019 Oct; 8(14):6403-6413. PubMed ID: 31475468
[TBL] [Abstract][Full Text] [Related]
17. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
[TBL] [Abstract][Full Text] [Related]
18. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
[TBL] [Abstract][Full Text] [Related]
19. Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
Jordheim LP; Dumontet C
Biomark Med; 2013 Aug; 7(4):663-71. PubMed ID: 23905902
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
